INTRODUCTION {#s1}
============

Interleukin-6 (IL-6) is one of the most widely recognized cytokines. It can regulate immune responses and cell proliferation and differentiation \[[@R1]\]. IL-6 was originally studied as an inflammatory factor, which was later found to be closely related to tumorigenesis, invasion and metastasis \[[@R2]\]. High expression of IL-6 is associated with different cancer types, such as esophageal cancer, non-small cell lung cancer, endometrial cancer, breast cancer, prostate cancer, lung cancer, chronic lymphocytic leukemia and diffuse large B-cell lymphoma \[[@R2]--[@R5]\]. Therefore, IL-6 is closely related to tumor occurrence and development, and understanding the genetic diversity of IL-6 will be helpful for cancer risk prediction and gene therapy.

The human IL-6 gene is located on chromosome 7p21 which is identified as pro-inflammatory cytokine \[[@R6]\], and plays an important role in the pathogenesis of several types of cancers. The single nucleotide polymorphisms (SNPs) at the 50 flanking region of the IL-6 gene promoter (rs1800795, rs1800796 and rs1800797) can effect on IL-6 expression \[[@R7]--[@R9]\]. However, previous studies have conflicting results between IL-6 promoter (rs1800795, rs1800796 and rs1800797) and cancer susceptibility \[[@R10]--[@R99]\] and prognosis \[[@R40], [@R47], [@R53], [@R57], [@R63], [@R100]-[@R106]\].

To confirm whether IL-6 promoter polymorphisms are related to cancer risk, we performed this meta-analysis, aiming to measure the correlation between IL-6 promoter polymorphisms and cancer susceptibility and prognosis.

RESULTS {#s2}
=======

Characteristics of published studies {#s2_1}
------------------------------------

A flow chart was carefully identified of the search process in Figure [1](#F1){ref-type="fig"}. After duplicates removed, 16843 studies were retrieved (PubMed: 16457, Embase: 18324). Finally, ninety-seven studies were chosen, and the data was extracted. Seventy-eight studies reported the association between rs1800795 and cancer risk, twenty-one studies reported the association between rs1800796 and cancer risk, seventeen studies reported the association between rs1800797 and cancer risk, and twelve studies reported the association between IL-6 promoter polymorphisms and cancer prognosis. The genotype frequencies of IL-6 promoter in controls of each study met the HWE expectation (*P* \> 0.05). The genotype distributions of all studies are summarized in [Supplementary Tables 1](#SD2){ref-type="supplementary-material"}--[6](#SD4){ref-type="supplementary-material"}.

![Flow diagram of the study selection process](oncotarget-09-12351-g001){#F1}

Meta-analysis of rs1800795 polymorphism and cancer risk {#s2_2}
-------------------------------------------------------

Seventy-eight studies reported the association between rs1800795 and cancer risk. Our results showed that rs1800795 was significantly associated with increased cancer risk in allelic, dominant, recessive and additive models (OR = 1.05, 95% CI: 1.01, 1.09, *P* = 0.007, allelic models respectively) (Table [1](#T1){ref-type="table"}). Subgroup analysis indicated that rs1800795 was associated with a significantly higher risk of cancer in Asia (OR = 1.05, 95% CI: 1.01, 1.10, *P* = 0.003, allelic models respectively) (Table [2](#T2){ref-type="table"}) and Caucasian (OR= 1.04, 95% CI: 1.02, 1.06, *P* \< 0.001, allelic models respectively) (Table [2](#T2){ref-type="table"}) in all four gene model. Meanwhile, rs1800795 was significantly associated with increased risk of cervical cancer (OR = 1.13, 95% CI: 1.05, 1.21, *P* = 0.004, allelic models respectively) (Table [3](#T3){ref-type="table"}), colorectal cancer (OR = 1.10, 95% CI: 1.02, 1.19, *P* = 0.014, allelic models respectively) (Table [3](#T3){ref-type="table"}), breast cancer (OR = 1.08, 95% CI: 1.01, 1.19, *P* = 0.013, allelic models respectively) (Table [3](#T3){ref-type="table"}), prostate cancer (OR = 1.08, 95% CI: 1.03, 1.13, *P* = 0.005, allelic models respectively) (Table [3](#T3){ref-type="table"}), lung cancer(OR = 1.08, 95% CI: 1.02, 1.15, *P* = 0.003, allelic models respectively) (Table [3](#T3){ref-type="table"}), glioma (OR = 1.28, 95% CI: 1.13, 1.46, *P* \< 0.001, allelic models respectively) (Table [3](#T3){ref-type="table"}), non-hodgkin's lymphoma (OR = 1.25, 95% CI: 1.01, 1.51, *P* = 0.049, allelic models respectively) (Table [3](#T3){ref-type="table"}) and hodgkin's lymphoma (OR = 1.22, 95% CI: 1.02, 1.45, *P* = 0.030, allelic models respectively) (Table [3](#T3){ref-type="table"}) but not gastric cancer (OR = 0.95, 95% CI: 0.83, 1.08, *P* = 0.435, allelic models respectively)(Table [3](#T3){ref-type="table"}) and multiple myeloma (OR = 1.06, 95% CI: 0.88, 1.30, *P* = 0.559, allelic models respectively) (Table [3](#T3){ref-type="table"}) in all four gene model.

###### Meta-analysis of IL-6 promoter polymorphisms and cancer susceptibility

  Genetic model   No.of studies          Heterogeneity   OR      95% CI   *P* value   Model      
  --------------- ---------------------- --------------- ------- -------- ----------- ---------- ----------------------
  **rs1800795**   **78 (46096/56969)**                                                           
  G vs. C                                55.5%           0.000   1.05     1.01,1.09   0.007      Random-effects model
  GG+ GC vs. CC                          38.4%           0.000   1.04     1.01,1.08   0.021      Fixed-effects model
  GG vs. GC+CC                           55.1%           0.000   1.08     1.03,1.13   0.001      Random-effects model
  GG vs. GC                              53.4%           0.000   1.06     1.00,1.14   0.035      Random-effects model
  **rs1800796**   **21 (9930/13080)**                                                            
  C vs. G                                47.2%           0.008   1.11     1.04,1.18   \< 0.001   Fixed-effects model
  CC+ CG vs. GG                          34.4%           0.059   1.12     1.02,1.21   0.029      Fixed-effects model
  CC vs. CG+GG                           50.6%           0.003   1.09     1.03,1.16   0.045      Random-effects model
  CC vs. CG                              44.5%           0.013   1.04     1.01,1.09   0.010      Fixed-effects model
  **rs1800797**   **17 (9162/12724)**                                                            
  G vs. A                                0.0%            0.901   1.04     1.01,1.08   0.007      Fixed-effects model
  GG+ GA vs. AA                          0.0%            0.904   1.07     1.02,1.13   0.007      Fixed-effects model
  GG vs. GA+AA                           0.0%            0.493   1.06     1.03,1.09   0.004      Fixed-effects model
  GG vs. GA                              38.0%           0.020   1.03     1.00,1.08   0.035      Fixed-effects model

###### Meta-analysis of IL-6 promoter polymorphisms and cancer risk in ethnicity

  --------------------------------------------------------------------------------------------------------------------
  rs1800795       No.of\                Heterogeneity   OR      95% CI   *P* value   Model      
                  studies                                                                       
  --------------- --------------------- --------------- ------- -------- ----------- ---------- ----------------------
  **Asian**       **3 (1090/1482)**                                                             

  G vs. C                               75.5%           0.017   1.05     1.01,1.10   0.003      Random-effects model

  GG+ GC vs. CC                         47.1%           0.151   1.03     1.01,1.06   \< 0.001   Fixed-effects model

  GG vs. GC+CC                          66.8%           0.049   1.07     1.03,1.12   \< 0.001   Random-effects model

  GG vs. GC                             56.7%           0.100   1.06     1.01,1.12   0.002      Random-effects model

  **Caucasian**   75 (44895/55402)                                                              

  G vs. C                               49.7%           0.000   1.04     1.02,1.06   \< 0.001   Fixed-effects model

  GG+ GC vs. CC                         34.0%           0.001   1.05     1.02,1.09   0.004      Fixed-effects model

  GG vs. GC+CC                          51.4%           0.000   1.10     1.06,1.15   \< 0.001   Random-effects model

  GG vs. GC                             51.6%           0.000   1.08     1.03,1.14   0.004      Random-effects model

  **rs1800796**                                                                                 

  **Asian**       **12 (3574/4423)**                                                            

  C vs. G                               52.9%           0.013   1.08     1.03,1.14   \< 0.001   Random-effects model

  CC+ CG vs. GG                         28.3%           0.160   1.12     1.05,1.20   \< 0.001   Fixed-effects model

  CC vs. CG+GG                          54.9%           0.009   1.15     1.06,1.25   0.009      Random-effects model

  CC vs. CG                             53.2%           0.012   1.06     1.02,1.11   0.018      Random-effects model

  **Caucasian**   **9 (5679/8001)**                                                             

  C vs. G                               0.0%            0.651   1.05     1.01,1.10   0.003      Fixed-effects model

  CC+ CG vs. GG                         5.2%            0.392   1.05     1.02,1.09   \< 0.001   Fixed-effects model

  CC vs. CG+GG                          15.2%           0.299   1.06     1.02,1.11   0.002      Fixed-effects model

  CC vs. CG                             29.9%           0.180   1.04     1.02,1.06   \< 0.001   Fixed-effects model

  **rs1800797**                                                                                 

  **Asian**       **2 (187/495)**                                                               

  G vs. A                               0.0%            0.637   1.23     0.79,2.04   0.326      Fixed-effects model

  GG+ GA vs. AA                         0.0%            0.954   4.38     1.21,15.9   0.025      Fixed-effects model

  GG vs. GA+AA                          0.0%            0.589   0.86     0.48,1.34   0.405      Fixed-effects model

  GG vs. GA                             0.0%            0.377   0.38     0.21,0.68   0.001      Fixed-effects model

  **Caucasian**   **14 (8298/11573)**                                                           

  G vs. A                               0.0%            0.806   1.04     1.01,1.08   0.041      Fixed-effects model

  GG+ GA vs. AA                         0.0%            0.900   1.06     1.02,1.11   0.034      Fixed-effects model

  GG vs. GA+AA                          3.1%            0.418   1.06     1.01,1.11   0.014      Fixed-effects model

  GG vs. GA                             25.9%           0.122   1.03     1.01,1.06   0.002      Fixed-effects model
  --------------------------------------------------------------------------------------------------------------------

###### Subground of analyses of rs1800795 polymorphism and cancer risk

  ---------------------------------------------------------------------------------------------------------------------------------
  rs1800795                    No.of\                Heterogeneity   OR      95% CI   *P* value   Model      
                               studies                                                                       
  ---------------------------- --------------------- --------------- ------- -------- ----------- ---------- ----------------------
  **Cervical cancer**          **7 (1734/2272)**                                                             

  G vs. C                                            70.1%           0.003   1.13     1.05,1.21   0.004      Random-effects model

  GG+ GC vs. CC                                      58.5%           0.025   1.16     1.06,1.27   0.039      Random-effects model

  GG vs. GC+CC                                       58.7%           0.024   1.21     1.08,1.34   0.002      Random-effects model

  GG vs. GC                                          44.0%           0.098   1.19     1.08,1.30   0.003      Fixed-effects model

  **Colorectal cancer**        **14 (7399/9808)**                                                            

  G vs. C                                            63.7%           0.000   1.10     1.02,1.19   0.014      Random-effects model

  GG+ GC vs. CC                                      0.0%            0.515   1.13     1.04,1.22   0.003      Fixed-effects model

  GG vs. GC+CC                                       63.6%           0.000   1.11     1.01,1.22   0.047      Random-effects model

  GG vs. GC                                          54.6%           0.006   1.07     1.01,1.19   0.019      Random-effects model

  **Gastric cancer**           **4 (672/1614)**                                                              

  G vs. C                                            0.0%            0.776   0.95     0.83,1.08   0.435      Fixed-effects model

  GG+ GC vs. CC                                      0.0%            0.573   1.03     0.81,1.32   0.799      Fixed-effects model

  GG vs. GC+CC                                       0.0%            0.874   0.87     0.72,1.06   0.181      Fixed-effects model

  GG vs. GC                                          0.0%            0.409   0.85     0.69,1.05   0.122      Fixed-effects model

  **Breast cancer**            **13 (9532/15064)**                                                           

  G vs. C                                            57.8%           0.011   1.08     1.01,1.19   0.013      Random-effects model

  GG+ GC vs. CC                                      61.6%           0.004   1.19     1.04,1.34   0.011      Random-effects model

  GG vs. GC+CC                                       60.5%           0.005   1.20     1.06,1.25   0.028      Random-effects model

  GG vs. GC                                          57.2%           0.012   1.11     1.06,1.17   0.009      Random-effects model

  **Prostate cancer**          **5 (12169/13116)**                                                           

  G vs. C                                            31.0%           0.203   1.08     1.03,1.13   0.005      Fixed-effects model

  GG+ GC vs. CC                                      32.4%           0.193   1.11     1.04,1.18   0.003      Fixed-effects model

  GG vs. GC+CC                                       24.0%           0.254   1.13     1.05,1.22   0.008      Fixed-effects model

  GG vs. GC                                          15.4%           0.315   1.07     1.02,1.12   0.003      Fixed-effects model

  **Lung Cancer**              **4 (3203/3332)**                                                             

  G vs. C                                            0.0%            0.817   1.08     1.02,1.15   0.003      Fixed-effects model

  GG+ GC vs. CC                                      0.0%            0.912   1.06     1.01,1.11   0.002      Fixed-effects model

  GG vs. GC+CC                                       25.4%           0.258   1.07     1.03,1.12   \<0.001    Fixed-effects model

  GG vs. GC                                          0.0%            0.745   1.10     1.03,1.17   0.003      Fixed-effects model

  **Glioma**                   **3 (1082/1701)**                                                             

  G vs. C                                            0.0%            0.482   1.28     1.13,1.46   \< 0.001   Fixed-effects model

  GG+ GC vs. CC                                      67.6%           0.046   1.15     1.05,1.26   0.021      Random-effects model

  GG vs. GC+CC                                       77.9%           0.011   1.50     1.03,2.17   0.035      Random-effects model

  GG vs. GC                                          88.7%           0.000   1.55     1.05,2.72   0.012      Random-effects model

  **Multiple myeloma**         **5 (6013/6471)**                                                             

  G vs. C                                            0.0%            0.901   1.06     0.88,1.30   0.559      Fixed-effects model

  GG+ GC vs. CC                                      0.0%            0.987   1.00     0.66,1.53   0.992      Fixed-effects model

  GG vs. GC+CC                                       0.0%            0.617   0.95     0.70,1.28   0.733      Fixed-effects model

  GG vs. GC                                          0.0%            0.737   1.01     0.73,1.38   0.961      Fixed-effects model

  **Non-Hodgkin's lymphoma**   **4 (5609/5649)**                                                             

  G vs. C                                            60.9%           0.053   1.25     1.01,1.51   0.049      Random-effects model

  GG+ GC vs. CC                                      11.2%           0.337   1.26     1.03,1.54   0.022      Fixed-effects model

  GG vs. GC+CC                                       50.3%           0.110   1.20     1.04,1.40   0.015      Random-effects model

  GG vs. GC                                          20.1%           0.289   1.15     1.08,1.35   0.008      Fixed-effects model

  **Hodgkin's lymphoma**       **3 (533/484)**                                                               

  G vs. C                                            16.7%           0.301   1.22     1.02,1.45   0.030      Fixed-effects model

  GG+ GC vs. CC                                      0.0%            0.460   1.25     1.02,1.73   0.043      Fixed-effects model

  GG vs. GC+CC                                       0.0%            0.434   1.32     1.02,1.73   0.037      Fixed-effects model

  GG vs. GC                                          0.0%            0.601   1.28     1.08,1.68   0.013      Fixed-effects model
  ---------------------------------------------------------------------------------------------------------------------------------

Meta-analysis of rs1800796 polymorphism and cancer risk {#s2_3}
-------------------------------------------------------

Twenty-one studies reported the association between rs1800796 and cancer risk. Our results showed that rs1800796 was significantly associated with increased cancer risk in allelic, dominant, recessive, and additive models (OR = 1.11, 95% CI: 1.04, 1.18, *P* \< 0.001, allelic models respectively) (Table [1](#T1){ref-type="table"}). Subgroup analysis indicated that rs1800796 was significantly associated with increased risk of lung cancer (OR = 1.23, 95% CI: 1.11, 1.36, *P* = 0.002, allelic models respectively) (Table [4](#T4){ref-type="table"}), prostate cancer (OR = 1.13, 95% CI: 1.04, 1.23, *P* = 0.002, allelic models respectively) (Table [4](#T4){ref-type="table"}) and colorectal cancer (OR = 1.07, 95% CI: 1.04, 1.23, *P* \< 0.001, allelic models respectively) (Table [4](#T4){ref-type="table"}) but not gastric cancer (OR = 1.03, 95% CI: 0.82, 1.29, *P* = 0.786, allelic models respectively) (Table [4](#T4){ref-type="table"}) in all four gene model. Furthermore, rs1800796 was associated with a significantly risk of cancer in Asia (OR = 1.08, 95% CI: 1.03, 1.14, *P* \< 0.001, allelic models respectively) (Table [2](#T2){ref-type="table"}) and Caucasian (OR = 1.05, 95% CI: 1.01, 1.10, P-0.003, allelic models respectively) (Table [2](#T2){ref-type="table"}) in all four gene model.

###### Subground of analyses of rs1800796 polymorphism and cancer risk

  --------------------------------------------------------------------------------------------------------------------------
  rs1800796               No.of\              Heterogeneity   OR      95% CI   *P* value   Model      
                          studies                                                                     
  ----------------------- ------------------- --------------- ------- -------- ----------- ---------- ----------------------
  **Lung cancer**         **6 (1974/2879)**                                                           

  C vs. G                                     55.6%           0.046   1.23     1.11,1.36   0.002      Random-effects model

  CC+ CG vs. GG                               57.4%           0.039   1.17     1.09,1.26   0.012      Random-effects model

  CC vs. CG+GG                                62.0%           0.022   1.15     1.05,1.26   0.012      Random-effects model

  CC vs. CG                                   66.2%           0.011   1.18     1.11,1.27   0.008      Random-effects model

  **Prostate cancer**     **5 (2360/3872)**                                                           

  C vs. G                                     0.0%            0.803   1.13     1.04,1.23   0.002      Fixed-effects model

  CC+ CG vs. GG                               0.0%            0.623   1.18     1.09,1.25   0.018      Fixed-effects model

  CC vs. CG+GG                                0.0%            0.493   1.19     1.07,1.32   0.015      Fixed-effects model

  CC vs. CG                                   13.5%           0.328   1.16     1.06,1.28   0.014      Fixed-effects model

  **Colorectal cancer**   **2 (2581/3363)**                                                           

  C vs. G                                     0.0%            0.826   1.07     1.03,1.12   \< 0.001   Fixed-effects model

  CC+ CG vs. GG                               0.0%            0.859   1.08     1.02,1.15   \< 0.001   Fixed-effects model

  CC vs. CG+GG                                0.0%            0.865   1.10     1.02,1.19   0.006      Fixed-effects model

  CC vs. CG                                   0.0%            0.905   1.15     1.04,1.27   0.009      Fixed-effects model

  **Gastric cancer**      **2 (365/395)**                                                             

  C vs. G                                     0.0%            0.910   1.03     0.82,1.29   0.786      Fixed-effects model

  CC+ CG vs. GG                               0.0%            0.380   1.05     0.62,1.80   0.848      Fixed-effects model

  CC vs. CG+GG                                0.0%            0.602   1.04     0.78,1.38   0.807      Fixed-effects model

  CC vs. CG                                   26.6%           0.256   1.05     0.78,1.41   0.757      Fixed-effects model
  --------------------------------------------------------------------------------------------------------------------------

Meta-analysis of rs1800797 polymorphism and cancer risk {#s2_4}
-------------------------------------------------------

Seventeen studies reported the association between rs1800797 and cancer risk. Our results showed that rs1800797 was significantly associated with increased cancer risk in allelic, dominant, recessive, and additive models (OR = 1.04, 95% CI: 1.01, 1.08, *P* = 0.002, allelic models respectively) (Table [1](#T1){ref-type="table"}). Subgroup analysis indicated that rs1800797 has significant association in breast cancer (OR = 1.14, 95% CI: 1.06, 1.23, *P* = 0.002, allelic models respectively) (Table [5](#T5){ref-type="table"}), non-Hodgkin's lymphoma (OR = 1.09, 95% CI: 1.03, 1.05, *P* = 0.006, allelic models respectively) (Table [5](#T5){ref-type="table"}), B-NHL (OR= 1.10, 95% CI: 1.03, 1.18, *P* = 0.006, allelic models respectively) (Table [5](#T5){ref-type="table"}) and DLCBL (OR = 1.10, 95% CI: 1.01, 1.20, *P* = 0.006, allelic models respectively) (Table [5](#T5){ref-type="table"}) but not gastric cancer (OR = 1.04, 95% CI: 0.93, 1.15, *P* = 0.530, allelic models respectively) (Table [5](#T5){ref-type="table"}) in all four gene model. Besides, rs1800797 was associated with a significantly higher risk of cancer in Caucasian (OR= 1.04, 95% CI: 1.01, 1.08, *P* = 0.041, allelic models respectively) (Table [2](#T2){ref-type="table"}) but not in Asia (OR = 1.23, 95% CI: 0.79, 2.04, *P* = 0.326, allelic models respectively) (Table [2](#T2){ref-type="table"}) in all four gene model.

###### Subground of analyses of rs1800797 polymorphism and cancer risk

  -------------------------------------------------------------------------------------------------------------------------------
  rs1800797                    No.of\              Heterogeneity   OR      95% CI   *P* value   Model      
                               studies                                                                     
  ---------------------------- ------------------- --------------- ------- -------- ----------- ---------- ----------------------
  **Breast Cancer**            **2 (1164/1388)**                                                           

  G vs. A                                          0.0%            0.705   1.14     1.06,1.23   0.002      Fixed-effects model

  GG+ GA vs. AA                                    0.0%            0.923   1.09     1.02,1.16   \< 0.001   Fixed-effects model

  GG vs. GA+AA                                     0.0%            0.454   1.17     1.09,1.15   0.003      Fixed-effects model

  GG vs. GA                                        0.0%            0.365   1.06     1.02,1.11   0.003      Fixed-effects model

  **Gastric cancer**           **2 (286/316)**                                                             

  G vs. A                                          0.0%            0.879   1.04     0.93,1.15   0.530      Fixed-effects model

  GG+ GA vs. AA                                    0.0%            0.692   1.01     0.82,1.24   0.936      Fixed-effects model

  GG vs. GA+AA                                     0.0%            0.662   1.06     0.92,1.23   0.429      Fixed-effects model

  GG vs. GA                                        4.0%            0.353   0.99     0.72,1.35   0.934      Fixed-effects model

  **Non-Hodgkin's lymphoma**   **4 (5729/6036)**                                                           

  G vs. A                                          0.0%            0.554   1.09     1.03,1.15   0.006      Fixed-effects model

  GG+ GA vs. AA                                    0.0%            0.497   1.07     1.02,1.13   0.002      Fixed-effects model

  GG vs. GA+AA                                     32.2%           0.219   1.12     1.04,1.21   0.008      Fixed-effects model

  GG vs. GA                                        67.6%           0.026   1.19     1.06,1.32   0.015      Random-effects model

  **B-cell lymphoma**          **3 (2161/2018)**                                                           

  G vs. A                                          0.0%            0.736   1.10     1.03,1.18   0.006      Fixed-effects model

  GG+ GA vs. AA                                    0.0%            0.389   0.83     0.50,1.37   0.462      Fixed-effects model

  GG vs. GA+AA                                     0.0%            0.603   1.39     1.12,1.67   0.007      Fixed-effects model

  GG vs. GA                                        58.3%           0.091   1.52     1.21,1.84   0.018      Random-effects model

  **DLCBL**                    **4 (5388/7026)**                                                           

  G vs. A                                          6.3%            0.344   1.10     1.01,1.20   0.006      Fixed-effects model

  GG+ GA vs. AA                                    0.0%            0.759   1.06     1.01,1.12   \< 0.001   Fixed-effects model

  GG vs. GA+AA                                     0.0%            0.683   1.13     1.03,1.24   0.003      Fixed-effects model

  GG vs. GA                                        0.0%            0.830   1.16     1.05,1.28   0.006      Fixed-effects model
  -------------------------------------------------------------------------------------------------------------------------------

DLCBL: diffuse large B-cell lymphoma.

Meta-analysis of IL-6 promoter polymorphisms and cancer prognosis {#s2_5}
-----------------------------------------------------------------

Twelve studies reported the association between IL-6 promoter polymorphisms and cancer prognosis. Prognostic meta-analyses were performed in a double gene model: CC vs. GC+GG and GG vs. GC+CC in rs1800795, GG vs. GC+CC in rs1800796 and GG vs. GA+AA in rs1800797. Our results showed that rs1800795, rs1800796 and rs1800797 were significantly associated with cancer prognosis (Table [6](#T6){ref-type="table"}).

###### Meta-analysis of IL-6 promoter polymorphisms and cancer prognosis

  ------------------------------------------------------------------------------------------------------------------
  Genetic model   No.of\               Heterogeneity   HR      95% CI   *P* value   Model      
                  studies                                                                      
  --------------- -------------------- --------------- ------- -------- ----------- ---------- ---------------------
  **rs1800795**   **10 (7640/8361)**                                                           

  GG vs. GC+CC                         0.088           43.6%   1.17     1.07,1.36   \< 0.001   Fixed-effects model

  CC VS. GC+GG                         0.610           0.0%    1.51     1.09,2.13   \< 0.001   Fixed-effects model

  **rs1800796**   **2 (452/538)**                                                              

  GG vs. GC+CC                         0.326           0.0%    1.16     1.07,2.42   \< 0.001   Fixed-effects model

  **rs1800797**   **3 (892/951)**                                                              

  GG vs. GA+AA                         0.416           0.0%    1.23     1.11,1.37   \< 0.001   Fixed-effects model
  ------------------------------------------------------------------------------------------------------------------

Sensitivity analysis {#s2_6}
--------------------

Sensitivity analysis was conducted to assess the stability of the results. The results show four genetic model were stable in [Supplementary Figures 1--3](#SD1){ref-type="supplementary-material"}.

Publication bias {#s2_7}
----------------

Each study in this meta-analysis was performed to evaluate the publication bias by both Begg's funnel plot and Egger's test. The results show no obvious evidence of publication bias was found in allelic, dominant, recessive or additive genetic model in Table [7](#T7){ref-type="table"}.

###### Publication bias analysis of the meta-analysis

  Genetic model   Test          t            95% CI   *P*
  --------------- ------------- ------------ -------- -------
  **rs1800795**                                       
  G vs. C         Begg's test                         0.853
  Egger's test    -1.49         -3.43,0.48   0.139    
  GG+ GC vs. CC   Begg's test                         0.272
  Egger's test    -4.09         -0.84,-027   0.125    
  GG vs. GC+CC    Begg's test                         0.472
  Egger's test    -3.27         -5.21,1.11   0.086    
  GG vs. GC       Begg's test                         0.791
  Egger's test    -1.74         -0.48,6.99   0.403    
  **rs1800796**                                       
  C vs. G         Begg's test                         0.602
  Egger's test    -4.82         -2.60,1.17   0.130    
  CC+ CG vs. GG   Begg's test                         0.117
  Egger's test    -9.04         -0.09,0.02   0.070    
  CC vs. CG+GG    Begg's test                         0.602
  Egger's test    -5.03         -3.15,1.36   0.125    
  CC vs. CG       Begg's test                         0.602
  Egger's test    -5.22         -2.82,1.17   0.121    
  **rs1800797**                                       
  G vs. A         Begg's test                         0.713
  Egger's test    -1.23         -8.24,2.07   0.230    
  GG+ GA vs. AA   Begg's test                         0.890
  Egger's test    -1.29         -0.87,0.20   0.211    
  GG vs. GA+AA    Begg's test                         0.931
  Egger's test    -0.86         -17.0,6.89   0.395    
  GG vs. GA       Begg's test                         0.973
  Egger's test    2.28          0.73,14.4    0.531    

DISCUSSION {#s3}
==========

Cancer is now a public health crisis, affecting millions of people in both developed and developing countries. By 2020, the disease is forecasted to be the major cause of morbidity and mortality in most developing nations \[[@R107]\]. To improve this embarrassing situation, risk factors concerning cancer should be identified timely and controlled effectively. The etiology of cancer involves both genetic and environmental factors. Therefore, understanding the impact of genetic factors on cancer will help to prevent cancer. IL-6 is a confirmed pleiotropic pro-inflammatory cytokine associated with cardiovascular diseases. Elevated expression of IL-6 and its major effector have been implicated in the different stages of cancer development, including initiation, promotion, malignant conversion, invasion, and metastasis \[[@R2]\].

Several recent meta-analysis have focused on the association between IL-6 promoter polymorphisms and cancer risk. Two meta-analysis showed that rs1800795 polymorphism increased the risk of prostate cancer and cervical cancer \[[@R108], [@R109]\]. Though, the result same with ours, it still exist some problems. On the one hand, single case-control studies with small sample sizes may have weak statistical power, thereby interfering with the precision of their results. On the another hand, the quantity of SNPs involving in their meta-analysis was smaller, which weak the persuasive power of their research. Additionally, no meta-analyses concerning the relationship between IL-6 promoter polymorphisms and cancer prognosis.

In this current meta-analysis was based on 97 case-control study, with 80361 cases and 78712 control from sixteen countries, thus, this meta-analysis provides the most up-to-date epidemiological evidence supporting IL-6 promoter polymorphisms were significantly associated with the susceptibility and prognosis of cancer. To our knowledge, this is the first complete study to identify the potential association between IL-6 promoter and cancer risk and prognosis. However, we also found rs1800795 was not associated with gastric cancer and multiple myeloma, this may be due to tumor heterogeneity or insufficient statistical power to check an association. therefore, a greater number of original case-control studies must be performed to further evaluate the association between the IL-6 promoter polymorphisms and different cancer types.

Although, we performed this meta-analysis very carefully, however, some limitations must be considered in the current meta-analysis. Firstly, we performed stratification only by ethnicity and cancer type, without referring other factors. Further research should be conducted in different sex of population. Secondly, we only select literature that written by English, other language should be chosen in the further. Thirdly, a lack of original data limited further evaluations of the potential gene-gene and gene-environment interactions.

In conclusion, our findings underscore the notion that IL-6 promoter polymorphisms were significantly associated with the susceptibility and prognosis of cancer. In the future, large-scale case-control and population based association studies must be performed in the future to validate the risk identified in the current meta-analysis, and investigate the effect of potential gene-gene and gene-environment interactions on cancer risk.

MATERIALS AND METHODS {#s4}
=====================

Search strategy and selection criteria {#s4_1}
--------------------------------------

The selection process is shown in the flow chart (Figure [1](#F1){ref-type="fig"}). We searched PubMed and Embase databases up to April, 2017, with keywords including "IL-6" or "interleukin-6" and "single nucleotide polymorphism" or "SNP" and "cancer" or "tumor". Eligible studies were choosing and other relevant publications were also examined.

Data extraction {#s4_2}
---------------

The following information in studies were investigated by two independent researchers: (1) first author; (2) publication year; (3) country; (4) cancer type; (5) cases and controls sample size; (6) genotype.

Statistical analysis {#s4_3}
--------------------

STATA software 12.0 (STATA Corp, College Station, TX, USA) was used to evaluate the relationships between IL-6 promoter polymorphisms and cancer risk and prognosis. Studies were assessed by chi-square in control group under Hardy-Weinberg equilibrium (HWE) to calculate frequencies of IL-6 promoter, and if *P* \< 0.05, study was considered to be disequilibrium. The strength of the relationship between IL-6 promoter polymorphisms and the risk of cancer were evaluated by odd ratios with corresponding 95% confidence intervals. The correlation between IL-6 promoter polymorphisms and prognosis of cancer were measured by hazard ratios (HRs). By using Q test and I^2^ statistic to assess heterogeneity among studies in rs1800795 in the allelic (G vs. C), dominant (GG+ GC vs. CC), recessive (GG vs. GC+CC) and additive (GG vs. GC), in rs1800796 in the allelic (C vs. G), dominant (CC+CG vs. GG), recessive (CC vs. CC+GG), and additive (CC vs. CG) genetic models and in rs1800797 in the allelic (G vs. A), dominant (GG+GA vs. AA), recessive (GG vs.GA+AA, and additive (GG vs. GA) genetic models. Random-effect model was chosen if *P*~Q~\<0.10 or I^2^ \>50%, otherwise, fixed-effect mode was applied. Sensitivity analysis was conducted to assess the stability of the results. Begg's and Egger's tests were used to assess the publication bias of each study.
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